Methods, Challenges, and Promise of Next-Generation Sequencing in Cancer Biology by Haimovich, Adrian D.
439
YALE JOURNAL OF BIOLOGY AND MEDICINE 84 (2011), pp.439-446.
Copyright ﾩ 2011.
REVIEw
Methods, challenges, and Promise of 
next-Generation Sequencing in cancer Biology
Adrian D. Haimovich
Yale School of Medicine, New Haven, Connecticut
It is generally accepted that cancers result from the aggregation of somatic mutations. The
emergence of next-generation sequencing (NGS†) technologies during the past half-decade
has enabled studies of cancer genomes with high sensitivity and resolution through whole-
genome and whole-exome sequencing approaches, among others. This saltatory advance
introduces the possibility of assembling multiple cancer genomes for analysis in a cost-ef-
fective manner. Analytical approaches are now applied to the detection of a number of so-
matic genome alterations, including nucleotide substitutions, insertions/deletions, copy
number variations, and chromosomal rearrangements. This review provides a thorough in-
troduction to the cancer genomics pipeline as well as a case study of these methods put into
practice.
IntroductIon
Over the course of the 10 years that have
passed  since  the  publication  of  the  first
human genome sequence, the landscape of
cancer research has changed with remarkable
speed. The completion of the human genome
project marked the beginning of a new era of
scientific research ― one in which the ge-
netic determinants of human disease could
be elucidated for a range of conditions based
on the appearance of unique genomic alter-
ations in groups of patients.
The fundamental hypothesis driving
disease genomics is that there is a constel-
lation of mutations that appear in affected
persons,  but  not  in  unaffected  persons.
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of common genomic polymorphisms, the
genomics community now has a large “nor-
mal” population against which mutations
identified in diseased populations can be
compared.  Single  nucleotide  polymor-
phisms (SNPs) are those mutations seen in
at least 1 percent of the population, while
single nucleotide variants (SNVs) include all
mutations, common and rare. In cancer ge-
nomics, there is one more level of compari-
son,  since  each  affected  person  has  two
types of tissue: tumor tissue and normal tis-
sue. By identifying those mutations that ap-
pear in tumor tissue but not in normal tissue,
the pool of total identified somatic variants
is further refined. The compendium of mu-
tations found in strictly disease tissues can
be evaluated for mechanistic impact.
Current understanding of cancer biol-
ogy allows for the classification of cancer
mutations into two categories: “drivers” and
“passengers” [1]. Driver mutations are those
that grant cells a survival advantage, while
the passenger mutations are those that have
been acquired at some point during clonal
evolution but do not provide a substantial
survival advantage. A major challenge of
cancer research is to differentiate these two
types of mutations. While driver mutations
are best confirmed in experimental models,
cancer genomics can aid in the identification
of putative candidates. 
As shown below, while NGS of cancers
affords a powerful pipeline for the discov-
ery of disease causing genomic variants,
there are numerous difficulties that increase
the complexity of research efforts. This re-
view endeavors to present a highly practical
overview of the discovery process in cancer
genomics.
readInG the GenoMe
The assembly of a reference genome by
the Human Genome Project was accom-
plished using capillary-based dideoxy-ter-
minator  sequencing  methods  termed
“Sanger” sequencing [2]. In “shotgun de
novo Sanger sequencing,” genomic DNA is
fragmented, cloned into a plasmid vector,
and then used to transform E. coli ― effec-
tively using bacteria to amplify the DNA
fragments. In the Sanger sequencing reac-
tion,  stochastically  incorporated  fluores-
cently labeled dideoxynucleotides (ddNTPs)
terminate the DNA extension reaction, and
the  sequence  is  determined  via  elec-
trophoretic separation of end-labeled ssDNA
in a capillary-based gel [3]. In this method,
96 or 384 capillaries provide one read each
per sequencing run [4]. 
Using  overlaps  in  sequenced  random
fragments, much longer sequences can be as-
sembled. Imagine, for example, that a se-
quence that reads WXY where W, X, and Y
represent long stretches of DNA. If another
sequence read UVW, it would be reasonable
to assemble the union of these two sequences
to read UVWXY. Assembly of the sequence
UVWXY depends on W being long enough
so that it would be very unlikely to appear
randomly. Therefore, shotgun de novoSanger
sequencing requires the same sequence to ap-
pear in multiple DNA fragments. Through
this laborious process, the NIH funded se-
quencing effort assembled a 90 percent com-
plete working draft of the human genome
more than a decade ago, which has since been
carried closer to completion [2]. 
Next-generation, or second-generation,
sequencing (NGS) encompasses a number of
different methodologies that have emerged
since 2005 [4,5,6,8,9]. In numerous NGS
methods, fragmented genomic DNA ligated
to universal adaptors are amplified into PCR
colonies or “polonies.” Each polony contains
many copies of the same fragment, and all of
the polonies can be sequenced in parallel
using arrays allowing millions of reads per
array [4]. Other NGS methods do not use
polonies, but instead read single DNA se-
quences [8]. While older NGS technologies
read sequence from one end of a given seg-
ment, newer methods allow for paired-end
reads. Once a sequence is read with NGS, it
is  aligned  to  the  most  current  reference
human genome (currently in its 19th itera-
tion as hg19). This mapping provides the
basis for all further analysis [9,10].
The general advantages of second-gen-
eration sequencing over Sanger sequencing
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are done in vitro, bottlenecks like transfor-
mation of E. coli are avoided. Second, there
is increased parallelism in second-generation
methods because they are based on arrays
rather than capillaries, which significantly re-
duces  sequencing  time.  Third,  since  the
polonies are all bound to the same array, they
can be treated with single reagent volumes
rather than multiple independent volumes,
thereby dramatically cutting costs [4]. 
Polonies are generated from single mol-
ecules, rather than working with a population
of molecules as in Sanger sequencing. Thus,
in NGS, there is a digital readout of tumor
mosaicism that is not captured in Sanger se-
quencing. This can be advantageous as the
mosaicism is anticipated in tumors, but at the
same time, low-frequency mosaicism is diffi-
cult to differentiate from stochastic or sys-
tematic errors. Collective NGS benefits are
offset by increased error rates as compared to
Sanger sequencing, as well as shorter read
lengths [4]. Though each NGS read has a rel-
atively high per-base error rate compared to
Sanger sequencing, a comparable consensus
genotype can be determined by reading a
given base many times, i.e., deep-sequencing.
Both whole-genome and whole-exome
sequencing can be carried out using Sanger
or NGS. Whole-exome sequencing is a tar-
geted strategy to capture the 1 to 2 percent of
the human genome that is protein coding
and contains the vast majority of disease-
causing mutations. While mutations identi-
fied in non-coding regions may in fact be
drivers of tumor progression, research ef-
forts focus primarily on mutations in exons
or at exon-intron boundaries because they
are more easily interpreted. 
For most users, the NGS sequencing
process entails isolating DNA from patient
samples and sending them to a core facility
for library preparation and sequencing. DNA
library preparation can be carried out by the
submitting lab in order to reduce costs and
increase control over samples. Depending
on the local sequencing pipeline, the facil-
ity will return summary data from the se-
quencing runs along with raw reads without
aligning  the  reads.  From  there,  publicly
available tools like bowtie, BWA, Maq, and
SOAP2 are used to generate sequence align-
ments, and, subsequently, variants are called
with programs such as SAMtools and GATK
[6,7,11-14].
‘callInG’ cancer MutatIonS 
Though a researcher presented with a
sequencing run summary and a list of po-
tential variants may feel prepared to begin
asking the biological questions that moti-
vated the study, there are numerous consid-
erations that require immediate attention.
Indeed, a cursory examination of the list will
likely reveal a large number of potential
variants in tumors and also in blood.
Before examining the mutation data, it is
pertinent to ask whether the sequencing itself
was  sufficiently  redundant  (or  “deep”)  to
allow confident mutation identification. There
are two simple metrics to evaluate depth of
coverage: mean coverage and percent of bases
covered at least N times. As a general guide-
line  in  exome  capture,  a  mean  coverage
greater than 100 times and percent of bases
covered at least 20 times greater than 90 per-
cent are desirable for the tumor sample due to
normal tissue contamination and tumor mo-
saicism. The purity of blood samples allows
for lower required redundancy.
For patient data where both tumor and
blood pass first inspection, the next task is to
filter automated sequencing calls. A single
tumor/blood pair can yield more than 20,000
hits, but there are numerous criteria used to
derive a working subset. For every called vari-
ant, the quality score ― the –log10 probabil-
ity that a variant call occurred by error as
based on the individual base qualities ― pro-
vides the first threshold [15,16]. Different
quality score thresholds of greater than 60 to
greater than 100 may be used; the experience
gained from initial sequencing efforts helps
set the scoring threshold in future experi-
ments. Non-synonymous, frameshift, splicing
and insertion/deletion mutations are typically
prioritized over synonymous changes because
they are more easily interpretable.
Given  a  genomic  coordinate  where
there is a putative difference between tumor
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test can be used to evaluate whether the se-
quencing read distributions differ signifi-
cantly. The Fisher exact test, in this case, is
used to identify non-random associations
between the number of each type of read
(variant or no-variant) and the sample (nor-
mal or tumor). The threshold for the Fisher
exact test can be set using the inverse of the
problem of interest. Specifically, one does
not expect to see variants in the blood/nor-
mal sample that are not in the tumor. Thus,
the p-value threshold can be set at a level
that rejects the blood variant calls [16].
Based on the expectation that disease-
causing mutations appear in a small percent-
age of the population, it is often advantageous
to further limit analysis to novel mutations.
dbSNP and the 1000 Genomes Project (and
soon the NIH Exome Project) provide a large
catalog of common variation across popula-
tions  [17,18].  The  strength  of  mutation’s
tumor driving potential is expected to be in-
versely correlated with its frequency in these
catalogs of common variants.
PIckInG the BattleS
At this point, synonymous mutations, low
quality variants, and variants found in both the
tumor and the normal samples have been ex-
cluded, effectively eliminating large swaths of
the variant pool. There may, however, be a
non-negligible number of misreads from the
NGS process requiring manual curation.
Using the sequence alignment files de-
scribed earlier, it is possible to visualize the
read alignments around a variant’s genomic
location in order to eliminate false positive
calls. This task may be accomplished with
publicly available software like the Inte-
grated Genome Browser or custom designed
programs [19]. 
In Figure 1, the reference genome appears
in the colored row at the top of the figure. The
white box above the reference genome marks
the location of the genomic locus of interest.
Aligned reads appear in the rows below the
reference genome. The colors of the boxes in
each position represent the base recognized by
NGS. In this example, red boxes represent ade-
nine, blue represent cytosine, green represent
guanine, and yellow represent thymine. The
degree to which the box is filled in with color
is proportional to the quality score of that base
on a given read, meaning a nearly black box
indicates a very low quality read for that spe-
cific base.
Figure  1A  shows  many  high-quality
reads of a tumor sample that contains a vari-
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Figure 1: Sample visualization of read alignments. In panels A and B, columns of inter-
est are denoted by white boxes at the top of the respective diagrams. The first colored
horizontal line represents the reference genome in each case. Red boxes represent ade-
nine, blue boxes represent cytosine, green boxes represent guanine, and yellow boxes
represent thymine. In (A), variant call is judged to be a correct read. In (B), variant call is
judged to be a misread. ant. To interpret this figure, focus on the
locus of interest in the reference genome as
highlighted by the white box at the top of the
image. The reference genome shows a yel-
low box at this locus, indicating that the ex-
pected base is thymine. In numerous reads
below the reference genome, the same col-
umn has filled-in blue boxes representing
cytosine. It can be concluded from these
data that there is a thymine to cytosine vari-
ation in the genome at this locus. The tumor
variant does not necessarily need to be rep-
resented in the majority of reads, as the
tumor samples are inherently mosaic and
frequently contaminated with normal tissue. 
Conversely, Figure 1B, which shows a
blue box at the locus of interest, has a num-
ber of reads with partially filled-in green
boxes representing guanine. The incomplete
filling of the green boxes indicates that these
are low quality reads. In addition, there are
many instances where the boxes adjacent to
the called variants are mostly black. This pat-
tern is associated with low base quality (in-
correct base calls) and incorrect alignment.
Together, these data suggest that the variant
shown in Figure 1B is a false positive. 
Visual analysis of read alignment fur-
ther trims the list of potentially significant
mutations but simultaneously highlights the
relatively high per-read error rate of NGS.
For this reason, mutations called by NGS
need to be confirmed via targeted Sanger se-
quencing or another validation method. Tar-
geted Sanger sequencing requires forward
and  reverse  polymerase  chain  reaction
(PCR) amplification of the region of inter-
est. Typically, greater than 100 base separa-
tion between the locus of interest and the
end of the primer is recommended, with a
maximum  read  length  of  approximately
1,000 bases and an ideal length of approxi-
mately 600 to 700 nucleotides [4]. Those fa-
miliar with working with human samples
will be aware of some of the complexities of
using PCR with human DNA. Specifically,
repeat regions and common variations found
in the human genome can cause the PCR
amplification to fail. There are many pub-
licly available tools designed to help avoid
these pitfalls, including SNPmasker [20] and
Primer3 [21]. After a successful PCR con-
firmed by DNA gel electrophoresis of both
blood/normal and tumor DNA samples, the
products are sent to a core facility for se-
quencing. Since it may not be clear a priori
which mutations will ultimately be of inter-
est, it is reasonable to attempt to confirm as
many calls with targeted Sanger sequencing
as reasonably possible.
MutatIonS to MechanISM
The great intellectual challenge in can-
cer genomics lies in relating confirmed mu-
tations to protein function. In a best-case
scenario, the disease cohort will have multi-
ple patients with mutations in the same gene.
This scenario may be considered low-hang-
ing fruit for follow-up analysis. It is worth
considering, however, the probability that n
mutations in a single gene will appear in a
cohort of X samples at random. Existing
datasets or statistical estimates can be used
to obtain an estimate of how often a gene is
mutated in the general population. Logically,
two mutations in a single gene in a cohort of
eight patients is more striking than two mu-
tations in a cohort of 20 patients, and the
Fisher exact test, among other statistical
tools, will yield a more precise estimate of
significance of a finding. Another method to
assess significance is to simulate numerous
draws of X patients from an existing dataset
of non-diseased samples and count the num-
ber of times n mutations in this single gene
occurs, creating a probability distribution by
Monte Carlo simulation [22].
In silico, there are a number of methods
by which the import of a given confirmed mu-
tation is estimated. It is important to understand
that none of these methods are in and of them-
selves sufficient evidence, but all can contribute
to the development of a hypothesis. PolyPhen2
uses sequence and structural features along
with a classification algorithm to present the
probability a given mutation will be deleteri-
ous  [23].  Sorting  Intolerant  from  Tolerant
(SIFT) uses sequence homology to predict ef-
fect of amino acid substitution on protein func-
tion [24]. Conservation, a useful metric for
evaluating the importance of a residue, pro-
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ability. The functional significance of a residue
is hypothesized to be proportional to its degree
of conservation [25]. Conservation at a given
locus does not require software-based evalua-
tion. The UCSC genome browser, among other
tools, shows conservation across species and
can be used to visualize wider regions [26]. In
addition to conservation, the function of multi-
ple  protein  domains  has  been  elucidated.
UniProtKB/Swiss-Prot is an excellent resource
for identifying protein domains [27].
It is often of interest to study proteins
in a network or pathway context. The Kyoto
Encyclopedia  of  Genes  and  Genomes
(KEGG) provides a searchable collection of
manually  collated  pathways  [28],  while
Gene Ontology (GO) annotation is a re-
source for defining gene product properties
[29]. GO annotation includes cellular con-
text, molecular function, and the essential
biological  processes  of  a  protein.  Other
pieces of publicly available software use lit-
erature scans and available datasets to de-
termine protein-protein interactions. Two
such examples are STRING (Search Tool for
the Retrieval of Interacting Genes/Proteins)
and GeneMANIA [30,31]. While very use-
ful, caution is required when using these re-
sources as multiple datatypes and datasets
have been integrated to create the shown in-
teraction networks. Ultimately, evidence of
interaction needs to be confirmed within the
cell or tissue type of interest.
Power oF cancer GenoMIcS
As is now readily apparent, hypothesis
generation in cancer genomics involves a
moderately  difficult  experimental  process
coupled  with  a  great  deal  of  informatics
work. Skills in a scripting language such as
Perl or Python prove invaluable in process-
ing the text-based data in an efficient manner
and, while not obvious, there are also non-
trivial computational considerations. Chief
among these is the very large storage re-
quirement for genomics data. Even with these
factors, cancer genomics has enabled new av-
enues of promising research and will un-
doubtedly continue to do so in the future.
A recent analysis of multiple myeloma,
a B-lymphoid malignancy, provides an ef-
fective case study for the concepts presented
in this review [32]. In this study, NGS was
used to sequence the whole-genome of 23
patients and the whole-exomes of 16 pa-
tients (with one patient overlap). Previous
studies of multiple myeloma have identified
activation of the MYC, FDFR3, KRAS, and
NRAS genes as well as of the NF-ʺB path-
way, and it was hypothesized that sequenc-
ing  would  reveal  biologically  relevant
patterns otherwise unobserved.
After assignment of a statistical thresh-
old based on background mutation rates and a
false discovery rate of ≤ 0.10, 10 genes in-
cluding KRAS (10 patients) and NRAS (9 pa-
tients) showed significant rates of non-silent
mutations. Six of these genes were novel as-
sociations in cancer. As discussed previously,
there are numerous methods by which the im-
port of mutations can be assessed, including
computational techniques, regional conserva-
tion, functional domains, and, perhaps most
importantly,  frequency  of  mutation  in  the
study cohort. The authors observed four mu-
tations in the DIS3 gene, all of which appear
in a highly conserved region that, based on
crystal  structures,  face  a  catalytic  pocket.
From an investigator’s perspective, these ob-
servations are highly suggestive of functional
significance. In addition, five patients showed
mutations in the uncharacterized FAM46gene. 
Gene Set Enrichment Analysis (GSEA)
is a simple, but powerful tool that identifies
coordinated changes in specified groups of
genes [33]. The authors used GSEA to show
a correlation between FAM46 expression
and the set of ribosomal proteins. Given
prior knowledge that DIS3 is involved in the
regulation of RNA levels and the correlation
between FAM46 and regulators of transla-
tion, the authors searched their pool of mu-
tations that did not pass significance testing
and found five other genes related to protein
translation and stability. At final count, 16
of the 48 patients had mutations affecting
translation and homeostasis. GSEA was also
used to link multiple singly occurring muta-
tions to the NF-ʺB pathway, as well as to hi-
stone modifying enzymes.
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Research in cancer genomics is enter-
ing a period of great promise, but also of
great expectation. Ongoing efforts to cata-
log mutations found in cancer are now being
coupled with a hunt for new therapeutic tar-
gets. While this search may reveal numer-
ous, low frequency driver mutations, new in
silico tools enable the consolidation of vari-
ants into specific pathways. An increasing
focus on these pathways will require the ap-
plication of more nuanced algorithms better
able to capture the network and evolution-
ary dynamics of tumor cells.
At the same time, ongoing sequencing
efforts will continue to generate massive
quantities of data. A major challenge in can-
cer genomics is the standardization, storage,
and public availability of these data. While
large consortia helped forge the field of can-
cer genomics, saltatory technological devel-
opments have opened the door to sequencing
for smaller research groups. With this devel-
opment, more teams are now pursuing par-
allel research goals, stressing the need for
continued collaboration and communication.
Similarly, as methods for data analysis in-
crease in sophistication and complexity, there
must be a focus on accessibility enabling un-
hindered information flow between compu-
tational and biological scientists.
As  shown  in  the  case  of  multiple
myeloma, NGS enables a powerful discov-
ery pipeline. Access to this pipeline, how-
ever, is governed by an understanding of the
core methods and limitations in cancer se-
quencing. As sequencing costs continue to
decline, there will be an expanded effort to
sequence matched tumor-normal DNA, but
this growth must be accompanied by in-
creased fluency in the terminology, tech-
niques, and challenges of cancer genomics.
Soon, data management and computation
will  replace  access  to  sequencing  as  the
major bottleneck in the discovery pipeline.
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